Year: 2022
Type: article
Study design: Observational Study
Abstract: BACKGROUND: Men with persistent risk of Grade Group (GG) ≥ 2 cancer after a negative biopsy present a unique clinical challenge. The validated MyProstateScore test is clinically-available for pre-biopsy risk stratification. In biopsy-naïve patients, we recently validated a straightforward testing approach to rule-out GG ≥ 2 cancer with 98% negative predictive value (NPV) and 97% sensitivity. In the current study, we established a practical MPS-based testing approach in men with a previous negative biopsy being considered for repeat biopsy. METHODS: Patients provided post-digital rectal examination urine prior to repeat biopsy. MyProstateScore was calculated using the validated, locked model including urinary PCA3 and TMPRSS2:ERG scores with serum PSA. In a clinically-appropriate primary (i.e., training) cohort, we identified a lower (rule-out) threshold approximating 90% sensitivity and an upper (rule-in) threshold approximating 80% specificity for GG ≥ 2 cancer. These thresholds were applied to an external validation cohort, and performance measures and clinical outcomes associated with their use were calculated. RESULTS: MyProstateScore thresholds of 15 and 40 met pre-defined performance criteria in the primary cohort (422 patients; median PSA 6.4, IQR 4.3-9.1). In the 268-patient validation cohort, 25 men (9.3%) had GG ≥ 2 cancer on repeat biopsy. The rule-out threshold of 15 provided 100% NPV and sensitivity for GG ≥ 2 cancer and would have prevented 23% of unnecessary biopsies. Use of MyProstateScore >40 to rule-in biopsy would have prevented 67% of biopsies while maintaining 95% NPV. In the validation cohort, the prevalence of GG ≥ 2 cancer was 0% for MyProstateScore 0-15, 6.5% for MyProstateScore 15-40, and 19% for MyProstateScore >40. CONCLUSIONS: In patients who previously underwent a negative prostate biopsy, the MyProstateScore values of 15 and 40 yielded clinically-actionable rule-in and rule-out risk groups. Using this straightforward testing approach, MyProstateScore can meaningfully inform patients and physicians weighing the need for repeat biopsy.
Institutions: University of Michigan, Michigan Medicine, Michigan Center for Translational Pathology, U-M Rogel Cancer Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Wayne State University, Johns Hopkins University, Johns Hopkins Medicine, Fred Hutch Cancer Center, Howard Hughes Medical Institute
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,480
Funders: Howard Hughes Medical Institute, U.S. Department of Health and Human Services, American Cancer Society, Prostate Cancer Foundation, A. Alfred Taubman Medical Research Institute, National Institutes of Health, Rogel Cancer Center, University of Michigan, National Institute on Aging, National Cancer Institute, National Institute of General Medical Sciences
Awards: G1348147509, G2000663719, Michigan Medical Scientist Training Program, G3671080452, G4376152923, G4797887072, Exploring Precision Oncology: From Gene Fusions to lncRNAs, G7640623676, Training in the Demography and Economics of Aging, The Early Detection Research Network: Data Management and Coordinating Center, Michigan Prostate SPORE 2025-2030, Michigan-VUMC Biomarker Characterization Center
OpenAlex ID: W4313340205